Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
SLO
Login
Search
Browsing
Upload document
Statistics
RUP
FAMNIT - Faculty of Mathematics, Science and Information Technologies
FHŠ - Faculty of Humanities
FM - Faculty of Management
FTŠ Turistica - Turistica – College of Tourism Portorož
FVZ - Faculty of Health Sciences
IAM - Andrej Marušič Institute
PEF - Faculty of Education
UPR - University of Primorska
ZUP - University of Primorska Press
COBISS
University of Primorska, University Library - all departments
First page
/
Show document
Show document
A-
|
A+
|
Print
Title:
Guide to reform of higher education : a European perspective
Authors:
ID
Jacobs, Bas
(Author)
ID
Ploeg, Frederick van der
(Author)
Files:
http://www.cepr.org/pubs/dps/DP5327.asp
Language:
English
Work type:
Not categorized
Organization:
UPR - University of Primorska
Keywords:
visoko šolstvo
,
reforme
,
bolonjski proces
,
Evropa
Place of publishing:
London
Publisher:
Economic Policy
Year of publishing:
2006
Number of pages:
1 v.
PID:
20.500.12556/RUP-4473
UDC:
371:378:81`373.61
COBISS.SI-ID:
2223575
Publication date in RUP:
10.07.2015
Views:
4195
Downloads:
33
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
JACOBS, Bas and PLOEG, Frederick van der, 2006,
Guide to reform of higher education : a European perspective
[online]. 2006. London : Economic Policy. [Accessed 2 April 2025]. Retrieved from: http://www.cepr.org/pubs/dps/DP5327.asp
Copy citation
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:
Voting is allowed only for
logged in
users.
Share:
Similar works from our repository:
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
Similar works from other repositories:
Vpliv izražanja receptorja za inzulinu podoben rastni dejavnik 1 (IGF1R) na preživetje pri razsejanem nedrobnoceličnem raku pljuč
Uravnavanje izražanja genov z načrtovanimi transkripcijskimi dejavniki, odvisnimi od kalcijevih ionov
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.
Comments
Leave comment
You must
log in
to leave a comment.
Comments (0)
0 - 0 / 0
There are no comments!
Back
